U.S. Court in DC Nixes Medicaid Rule Requiring Drug Makers to Count Certain Patient Assistance in “Best Price” Reporting
- May 20, 2022
The U.S. District Court for the District of Columbia vacated May 17 a Department of Health and Human Services (HHS) final rule that required drug manufacturers to count certain patient financial assistance in their “best price” reporting for purposes of the Medicaid rebate statute.
ARTICLE TAGS
You must be logged in to access this content.